BLAINJECTIONINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PYZCHIVA (ustekinumab-ttwe) by Samsung Bioepis is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYZCHIVA (ustekinumab-ttwe) is a monoclonal antibody biosimilar that antagonizes interleukin-12, modulating immune response in inflammatory and autoimmune conditions. As a biosimilar, it replicates the mechanism of the reference biologic ustekinumab. The injectable formulation targets patients with conditions where IL-12 pathway inhibition provides therapeutic benefit.
Growth
Early-stage biosimilar entering growth phase with moderate competitive pressure (30/100), creating opportunity for launch-focused commercial teams but long-term market share uncertain.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PYZCHIVA offers early career visibility in biosimilar launch execution, a growing specialty within pharma. Roles emphasize formulary strategy, payer negotiation, and physician education rather than long-term innovation.
Brand ManagerMarket Access Manager
Worked on PYZCHIVA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.